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Non-Malignant Cardiac Tumors
Sarah Eapen, Bethany Malone, Jennifer Hanna 
and Michael S. Firstenberg
Abstract
Cardiac tumors represent an unusual clinical problem in that they are often 
discovered as an incidental finding during a routine echocardiogram or in the 
course of a work-up for a source of embolism. Malignant tumors of the heart are 
either defined as primary or metastatic from an extra-cardiac primary source—
regardless, the prognosis is poor. However, there are several cardiac tumors that are 
characterized as being non-malignant with regard to their tumor biology, but their 
tendencies to cause embolic or obstructive complications can be just as catastrophic 
despite a lack of invasiveness or potential to metastasize. The purpose of this chap-
ter is to review the common types of non-malignant cardiac tumors with regard to 
their incidence, presentation, potential for complications, and management—with 
emphasis on surgical indications and techniques.
Keywords: cardiac tumor, myxoma, fibroelastoma, cardiac surgery, benign tumors, 
cardiac lipomas, heart disease
1. Introduction
Embolic strokes are one of the most devastating medical conditions with regard 
to the overall impact on quality and quantity of life. Once an embolic complication 
occurs, management options are sometimes limited, but a critical aspect of appro-
priate disease management is searching for a source of embolism. The same con-
cepts hold true with peripheral embolisms. Part of the rationale for the search for 
a source is to help determine optimal therapies with the goal of reducing addition 
embolic events and further complications. Despite substantial resources devoted to 
stroke (and embolic) prevention, it still remains a considerable problem.
A recent report by the American Heart Association illustrates the enormous 
burden that strokes represent to society. A cerebrovascular event (i.e., a stroke) 
occurs every 40 seconds in the United States with a related death occurring every 
3.7 minutes [1]. While the causes of strokes are complex and often multi-factorial, 
cardiac sources represent a common etiology. Atrial fibrillation and associated left 
atrial appendage thrombi are one of the more frequently encountered sources [2]. 
Even though mechanical left atrial appendage closure or systemic anticoagulation 
remain the standard of care for treatment [3], it is important to consider that there 
are a variety of other cardiac-related causes of embolism and stroke. The most com-
mon non-thrombotic causes of cardiac embolism are infectious and non-infectious 
endocarditis—a topic that is the focus of other chapters [4].
The focus of this chapter is non-malignant and non-infectious cardiac 
masses—with an emphasis on diagnosis and management. Cardiac tumors are often 
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delineated as malignant and non-malignant with malignant tumors being either 
primary (i.e., cardiac sarcomas) or metastatic (i.e., breast carcinoma). They are 
distinguished from non-malignant tumors, such as myxomas and fibroelastomas, 
in that the latter, despite the pathologic implications of growth (i.e., valvular 
obstruction) and systemic embolism, lack true metastatic potential. Nevertheless, 
non-malignant cardiac tumors can be clinically devastating (i.e., malignant) by 
their tendency to cause potentially devastating, and occasionally fatal, embolic 
complications [5].
2. Methods
The focus of this review is on non-malignant tumors. The review methods 
consisted of Google Scholar (https://scholar.google.com) and PubMed (https://
www.ncbi.nlm.nih.gov/pmc/) searches with emphasis on the following key words: 
cardiac tumors, benign cardiac masses, myxomas, fibroelastomas, and fibromas. 
Additional associated search terms included: surgery, diagnosis, imaging, and 
management. Selected references, including manuscript abstracts and full texts, 
were reviewed for relevance in the context of this review.
3. Myxomas
Cardiac tumors are rare, occurring at a frequency of 0.0017–0.33% [6]. Cardiac 
myxomas are one of the most common, comprising 77% of surgically excised 
tumors in autopsy series [7]. Myxomas affect females predominantly with an 
incidence 1.5–2 times that of males [8]. The average age at presentation is 53 [8]. The 
majority of myxomas are sporadic. Inherited forms are less common, seen in 7% of 
myxomas [9]. Initially reported by Carney in 1985, cardiac myxomas seen in asso-
ciation with pigmented skin lesions and endocrine tumors are collectively known as 
Carney complex, an autosomal dominant genetic disorder. Familial myxomas tend 
to affect younger patients and have a higher prevalence among females. In addition, 
they are more often multicentric with higher rates of embolism and recurrence 
following resection [9].
Myxomas tend to be rare tumors of mesenchymal origin. They are comprised of 
stromal cells and are characterized as being benign (Figure 1). Biochemically, they 
Figure 1. 
Histology of cardiac myxoma. Representative histology of cardiac myxoma tissue in a 26-year-old woman with 
multiple recurrences of cardiac myxoma (HE, 100×). A: Tumor in 2005. B: Tumor in 2010. Similar histologic 
appearance of A and B with irregular and papillary proliferations in the myxoid stroma. Bar = 30 μm [10].
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have been correlated with increased production of interleukin 6 (IL-6), however, 
the significance of this is unclear [11]. While ocular, cutaneous, intramuscular, and 
juxta-articular involvement has been described, the most common presentation is 
intra-cardiac with most (85%) involving the left atrium [12].
Cardiac myxomas are typically solitary lesions and most commonly arise from 
the septal endocardium near the fossa ovalis [8]. 85% arise from the left atrial 
septum and 11% arise from the right atrial septum [7]. The clinical presentation of 
myxomas is dependent on tumor location. When confined to the left atrium, myxo-
mas present with symptoms of mitral valve stenosis [13]. Dyspnea and orthopnea 
result from pulmonary edema and left-sided heart failure. Conversely, right atrial 
myxomas cause tricuspid valve stenosis, leading to symptoms of right-sided heart 
failure [13]. In 22% of patients, embolism may occur, leading to symptoms of 
peripheral ischemia or stroke [8]. 20% of patients develop systemic symptoms, 
which are attributed to production of IL-6 by tumor cells [14]. Rarely, myxomas 
may become infected with symptoms similar to those of infective endocarditis [13].
Echocardiography is the primary diagnostic modality for cardiac myxomas [15]. 
Typical echocardiographic findings are of a mobile mass arising from the septal 
endocardium, attached by a narrow stalk. Echocardiography is preferred to MRI 
and CT imaging due to enhanced spatial and temporal resolution. If echocardiogra-
phy is non-diagnostic, MRI findings of a heterogeneous mass bright on T2-weighted 
imaging and CT findings of a heterogeneous mass with low attenuation are consis-
tent with myxoma (Figures 2 and 3) [15]. Advanced imaging is often performed to 
help differentiate “benign” myxomas from more aggressive or potentially malignant 
cardiac tumors that might require a more comprehensive oncologic management 
strategy (i.e., aggressive debulking, adjuvant chemotherapy, or even palliative care 
for advanced tumors). While the imaging characteristics, as described above, of 
myxomas are often diagnostic, unusual appearing masses might prompt further 
imaging to rule-out other tissue types. The differential diagnosis for such masses 
includes teratomas (rare), lipomas, angiosarcomas, rhabdomyomas, and rhabdo-
myosarcomas [18]. Distinguishing characteristics often consist of intramyocardial 
tumor invasion on imaging. Tissue biopsy is rarely indicated as the risk of embolism 
from endomyocardial biopsies will typically prompt definitive surgical resection 
for primary diagnosis and therapeutic intervention. Tumor location and imaging 
characteristics, along with a detailed history and physical, can also help distinguish 
cardiac tumors from other types of intra-cardiac pathology, such as endocarditis or 
thrombus. A recent history of acute myocardial infarction or known left ventricular 
Figure 2. 
Representative echocardiographic images of a large left atrial myxoma. From: Surgical resection of cardiac 
myxoma. Images of a rapidly growing myxoma. (a): A small myxoma is attached to the left atrial side of the 
fossa ovalis. (b): An enlarged myxoma passes in and out of the mitral valve according to the cardiac cycle [16].
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dysfunction might predispose to apical thrombus just as a history of atrial fibrilla-
tion is known to predispose to left atrial or left atrial appendage thrombus [19, 20].
Histologically, myxomas are composed of stellate mesenchymal cells in a 
background of myxoid stroma. Myxoma cells are variably positive for S-100, CD31, 
and CD34 [13]. In addition, 73.9% of cardiac myxomas express calretinin [21]. 
Inactivating mutations in the PRKAR1A gene are observed in both sporadic and 
non-sporadic myxomas. For this reason, routine immunohistochemical staining for 
PRKAR1A is recommended [22].
Recommended treatment for suspected cardiac myxomas, regardless of size, is 
immediate surgical resection due to embolic risk [23]. Tumor size ≥ 4.5 cm and soft 
tumors have been identified as independent risk factors for embolism. Prognosis 
is favorable with a 92.7% 10-year survival rate following surgical resection. Tumor 
recurrence is extremely rare. Multicentricity, observed with Carney complex, is an 
independent risk factor for recurrence following surgical resection [23]. Recurrence 
has been associated with incomplete resection and family history of complex or 
multiple myxomas [24]. In general, recurrence rates are typically less than 3%, 
often in complex or unusual cases [25].
4. Papillary fibroelastomas
Papillary fibroelastomas comprise less than 10% of primary cardiac tumors 
and are the most common primary tumor of cardiac valves (Figure 4) [14]. Men 
and women are affected equally at an average age of 60. Fibroelastomas are now 
thought to be more prevalent than myxomas, contradicting previous autopsy 
series in which myxomas were the most common primary intracardiac tumor 
[26]. Their etiology is unclear with development related to organizing thrombi, 
hamartoma proliferation, chronic viral endocarditis, and repeated hemodynamic 
trauma [27]. Iatrogenic cases of fibroelastomas following thoracic radiation and 
cardiac surgery have also been described, though these are typically non-valvular 
[28]. Fibroelastomas are valvular in 90% of cases, most commonly involving the 
aortic and mitral valves [29]. Less commonly, the left ventricular endocardium and 
tricuspid valves are affected [15]. Diseased valves are affected in 69.5% of cases, 
specifically post-rheumatic valves in 37.8% and fibrotic calcified valves in 62.2%. 
This finding has led some to speculate that a contributing factor to their develop-
ment is repeated trauma to the cardiac valve surface from abnormal intra-cardiac 
blood flow and turbulence [13].
Figure 3. 
Representative cardiac MRI demonstrating a right atrial myxoma. Right atrial myxoma causing syncope.  
A: Cardiac MRI showing atrial myxoma during systole. B: Cardiac MRI showing atrial myxoma during 
diastole. RA, Right atrium; RV, Right ventricle; LA, Left atrium; LV, Left ventricle; arrow—Myxoma [17].
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Clinically, fibroelastomas may present with acute embolism following platelet 
and fibrin aggregation [8]. Alternatively, prolapse of fibroelastomas adjacent to 
coronary ostia may lead to angina, syncope, and sudden death. The diagnosis is 
made by echocardiography, which demonstrates a small, homogenous mobile 
mass attached to a valve by a short pedicle [15]. They have characteristic papillary 
fronds and resemble sea anemones (Figure 5) [31]. These papillary projections give 
fibroelastomas characteristic stippled edges on echocardiographic imaging [32]. 
Fibroelastomas may be mistaken for Lambl’s excrescences, which are mobile frond-
like lesions that occur along lines of valve closure [33]. Interestingly, there have 
been some anecdotal reports of spontaneous regression. For this reason, intraopera-
tive transesophageal echocardiography is clearly indicated prior to surgical inter-
vention [34]. However, these reports should not be used to advocate non-operative 
management except in very high-risk patients. In addition, there is no evidence to 
suggest a role for anti-platelet or anti-coagulation therapy as a means of treatment 
or secondary prevention once an embolic complication occurs. Nevertheless, in 
Figure 4. 
Surgical specimen of a fibroelastoma. Surgical specimen of an incidental 5 mm fibroelastoma found during 
routine intra-operative transesophageal echocardiography in a patient undergoing routine coronary artery 
bypass surgery.
Figure 5. 
Photomicrograph of a fibroelastoma. Photomicrograph of papillary fibroelastoma. From: Robotic excision of 
aortic valve papillary fibroelastoma and concomitant maze procedure [30].
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patients who are not surgical candidates, such medical therapy might be reasonable. 
In theory, very small tumors could be drawn into the cardiopulmonary bypass cir-
cuit or surgical suction prior to excision precluding pathologic evaluation. In such 
cases, pre- and post-bypass imaging is critical to not only confirm the diagnosis, but 
also to demonstrate resection.
Although transthoracic echocardiography can be used to screen for papillary 
fibroelastomas, transesophageal echocardiography is preferred due to higher resolu-
tion and enhanced imaging capability (Figure 6) [36]. Multiplanar transesophageal 
echocardiography identifies the exact point of endocardial attachment, which facili-
tates operative planning. One of the limitations of echocardiography is its inability 
to stratify risk of embolization based on lesion characteristics [37]. Fibroelastomas 
are usually not visualized on MRI and CT imaging [15]. Histologically, fibroelas-
tomas have a central core of dense connective tissue, which is surrounded by loose 
connective tissue and lined with hyperplastic endothelial cells [31]. These surface 
endothelial cells express vimentin and CD34. These findings have unclear clinical 
significance, but are helpful in establishing a pathologic diagnosis [13].
Surgical resection sparing underlying valve tissue is recommended in cases of 
papillary fibroelastoma. In a study of 511 cases over a 15-year period at the Mayo 
Clinic, 185 patients (36.2%) underwent surgical resection [37]. Primary excision was 
performed in 51% while excision as an adjunct to other cardiac surgery was performed 
in 49%. The aortic valve was most commonly affected and in 98% of cases, the native 
valve was preserved. Three hundred and twenty-six patients (63.8%) with echo-
cardiographic findings of papillary fibroelastoma were managed non-operatively. 
Patients with papillary fibroelastoma suspected on echocardiography who did not 
undergo surgical resection had higher rates of stroke and mortality [37].
In the above described Mayo Clinic operative series, there was a 98% native valve 
preservation rate and 1.6% recurrence rate. Most importantly were their neurologic 
embolic outcomes. For the surgical population, the stroke risk was 2% at 1 year and 
8% at 5 years. This rate was approximately 2.5x age-matched controlled. For the 
medically managed patients, the 1- and 5-year stroke risk was significantly higher 
than the operative group at 6 and 13%, respectively. There were 29 observed strokes 
versus 8.4 expected. Obviously, it was difficult to determine the impact of con-
founding risk factors that might have increased the stroke risk in patients who were 
otherwise poor surgical candidates. Regardless, the incidence was still nearly 3.5× 
that of matched controls. Furthermore, in the non-operative group, medical man-
agement with anti-thrombotic therapy (i.e., anti-platelet and anti-coagulant therapy, 
including dual therapy) had no impact on the stroke risk at 5 years when compared 
Figure 6. 
Echocardiographic imaging of a fibroelastoma. Fibroelastoma of the aortic valve. Short and long axis view 
transesophageal echocardiography. From: Surgery for cardiac papillary fibroelastoma: A 12-year single 
institution experience [35].
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to those without anti-thrombotic therapy [37]. Overall, the authors did not find any 
echocardiographic or clinical variables that helped stratify patients into high- or 
low-risk groups for embolic complications. The significant increased stroke risk in 
the non-operative group (even when matched for age-adjusted controls) and the lack 
of benefit of medical therapies serve as contemporary evidence to justify surgical 
management as first-line therapy in appropriate risk-stratified patients (Figure 7).
Surgical intervention for papillary fibroelastoma should be considered in 
patients who are symptomatic, undergoing cardiac surgery for other reasons, or 
have large, highly mobile lesions [38]. Further study through randomized con-
trolled, multicenter trials is needed to determine if the potential benefit of surgical 
resection outweighs risk in asymptomatic patients. In asymptomatic patients who 
are otherwise good surgical candidates, the decision for non-operative management 
should be well-documented as part of shared decision-making with the patients 
with emphasis on the theoretical risks and benefits of surgery versus the risks of 
embolic complications.
In another single-center review, there was a tendency for occurrence in elderly 
males (71% males and 57% older than 61 years of age). Most (72%) occurred on 
a cardiac valve. Rarely was more than 1 lesion encountered and rarely were they 
>1.5 cm in size (27.8%). Surgical management was uncomplicated in all cases, even 
though some patients required concomitant surgery (i.e., coronary artery bypass 
grafting), and 30-day survival was 100%. No recurrences were reported at 1-year 
follow-up [39]. Similar outcomes were reported from another large-volume pro-
gram in which Mkalaluh and colleagues reported 0 peri-operative mortalities in 11 
patients (7 of whom had valvular involvement) with 100% 1-year survival and 91% 
survival at a mean follow-up of 4.2 years [40].
The indications for surgical resection are often a function of presentation and 
whether the patient is an appropriate surgical candidate. Since many fibroelastomas 
are incidental findings and hence asymptomatic, the natural history is unclear even 
though their tendency to embolize as pedunculated masses is unpredictable. For 
this reason, in appropriate surgical candidates, the presence of a presumed fibro-
elastoma is often an indication for surgical management, especially with left-sided 
Figure 7. 
Proposed algorithm for left-sided possible fibroelastoma. Legend: Adopted from Tamin et al. [37].  
FE: Fibroelastoma. *Note: there is little evidence to support the overall recommendation for anti-platelet or 
anti-coagulant therapy in this population.
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lesions. While tumor size has not been correlated with embolic risk [41], there is 
some evidence to suggest that in medically managed patients, the risk of neurologic 
events was as high as 22% [42]. Nevertheless, the risks of non-operative manage-
ment are poorly understood. Advocating for surgical intervention must be individu-
alized as part of shared decision-making [43].
5. Cardiac lipomas
Cardiac lipomas, much like lipomas encountered elsewhere in the body, are 
typically composed of mature adipose (fat) cells and are well-encapsulated. The 
majority of cardiac lipomas are subendocardial (50%), while the remainder are 
myocardial (25%) or subpericardial (25%) (Figure 8). They are typically found in 
the left ventricle or right atrium. Embolic complications are extremely rare unless 
the tumor is coated with thrombus from abnormal flow patterns. Typically, the 
presentation is characterized by obstructive symptoms [46, 47]. Surgical resection 
is typically reserved for symptomatic patients and consistent of removal of the 
entire capsule with pericardial reconstruction of the residual defect if necessary 
[48]. Asymptomatic patients can be managed expectantly. It is important to note 
that lipomas must be distinguished from lipomatous hypertrophy of the intra-atrial 
septum. Lipomatous hypertrophy is considered a benign infiltrative process of 
the adipose septal tissue. However, obstructive symptoms and even complex atrial 
arrhythmias can develop from cellular proliferation. In such symptomatic cases, 
surgical debulking and reconstruction may be considered [49].
6. Unusual/rare non-malignant cardiac tumors
While myxomas and fibroelastomas are the most common forms of non-
malignant cardiac tumors, other cellular types have been encountered as 
intra-cardiac masses. Most are considered extremely rare and limited to cases 
Figure 8. 
MRI and surgical specimen of a cardiac lipoma. Left figure: Cardiac lipoma in the interventricular septum. 
Cardiac MRI showed a round-like signal, measuring 36 × 20 mm, in the upper portion of IVS, anterior to 
the right coronary sinus of aorta [44]. Right figure: Cardiac lipoma. The surface of the specimen is lined by 
smooth endocardial and epicardial tissue. The cut surface displays a yellow, lobulated appearance without 
hemorrhage, necrosis, fleshy change, or calcification [45]. Note: The surgical specimen is from the same patient 
as the MRI (both cc*: Figures with this marker are used under the terms of Creative Commons Attribution-
NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-
commercially, as long as the author is credited and the new creations are licensed under the identical terms).
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reports or small series from large institutions. These masses include teratomas, 
hamartomas, fibromas, hemangiomas, paragangliomas, and mesotheliomas of 
the atrioventricular node [50, 51]. Management is often similar to other cardiac 
masses and based on presenting symptoms, concern for embolic risk or obstruc-
tive physiology, and clinical risk of surgical intervention [52]. Because of the 
rarity of these types of tumors, little is known about pre-operative incidence. 
A definitive tissue diagnosis is often made at the time of surgical resection [53]. 
Unlike myxomas and fibroelastomas, embolic complications of these unusual 
tumors are rare. Patients typically present with obstructive heart failure symp-
toms. As most are asymptomatic, they are often only encountered at autopsy 
and are rarely considered the cause of death [54]. Resection or debulking is 
typically indicated based on presentation, tumor location (especially with 
regard to surrounding cardiac structures), and size. However, some patients 
with large tumors, presumed to be benign or potentially curative with resection, 
might need cardiac transplantation if safe resection is not possible [55]. Most 
ventricular fibromas can undergo safe resection, even if the tumor involvement 
is extensive, with good short- and long-term results and trivial risk of recur-
rence [56]. In general, symptoms of heart failure and arrhythmias resolve with 
resection. Asymptomatic tumors that fit into this category can be managed 
expectantly with serial imaging.
7. Surgical management of benign cardiac tumors
The surgical management of non-malignant cardiac tumors varies depending on 
the location of the tumor and the potential involvement of intra-cardiac structures 
[57]. Not only is the oncologic principle of wide excisional margins is not always 
possible due to the critical nature of certain cardiac structures, it is not necessary. 
The key principle is complex tumor excision if possible. Unless the diagnosis is 
obvious based on presentation, location, and clinical appearance, non-malignant 
tumors can often be confused with subacute endocarditis or intra-cardiac throm-
bus. Nevertheless, complex excision is necessary. Fibroelastomas can often be the 
easiest to remove, typically by sharp excision from their adherent structures. Even 
with valvular involvement, it would be uncommon to require leaflet reconstruction 
or valve replacement.
Intra-cardiac excisions, almost by definition, require cardiopulmonary 
bypass, aortic cross-clamping, and cardiac arrest. The specific techniques are 
beyond the scope of this chapter, as are the advantages and disadvantages of 
choice of incision (i.e., conventional full sternotomy, minimally-invasive sternal 
or right thoracotomy, or robotic-assisted techniques) and myocardial protec-
tion. The approach is probably best left to the individual comfort level and skill 
of the surgeon [58]. Nevertheless, because focused resection compared to wide 
debridement is typically the surgical goal, minimally-invasive approaches may 
be reasonable in appropriately selected patients. Cannulation techniques will 
vary depending on the tumor location. However, there should be a low threshold 
for bi-caval cannulation to assist in access to the atrial chambers and possible 
resection and reconstruction of the intra-atrial septum. In addition, root venting 
should always be considered, even with primary right-sided structures, as com-
munication or left-sided involvement might introduce intra-cardiac air that would 
require appropriate de-airing upon weaning from cardiopulmonary bypass. 
In patients with concomitant cardiovascular pathology (i.e., coronary artery 
disease, aortic aneurysms, or separate valvular pathology), appropriate surgical 
intervention should be performed. The decision to perform a preoperative cardiac 
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catheterization should be based on an appropriate multi-disciplinary assessment 
of the risks of underlying coronary artery disease, risks of the procedures (i.e., 
catheter-induced dislodgement of the tumor), and the age and co-morbidities of 
the patient as suggested by clinical guidelines [59]. In situations in which cardiac 
catheterization is either relatively contraindicated (i.e., presence of an aortic valve 
mass) or perceived to be of low clinical benefit, coronary computed tomography 
might be considered and potentially helpful in guiding therapy [60]. Intra-
operative transesophageal echocardiography should be used routinely to ensure 
an accurate diagnosis, clear identification of involved structures, and complete 
resection prior to surgical closure [61].
For tumors that involve either the aortic valve or left ventricular outflow track, the 
surgical approach should be trans-aortic—essentially a similar approach as is used 
for traditional aortic valve replacement surgery. Aortic valve replacement is rarely 
necessary. Careful trans-aortic exposure to the left ventricular outflow track can 
provide access to tumors in the LVOT or on the left ventricular side of the anterior 
leaflet of the mitral valve. Even residual aortic or mitral insufficiency, either primary 
insufficiency or as a consequence of resection, can be well tolerated for many years. 
The indications for valve replacement in such cases should be limited to those patients 
in whom residual regurgitation would otherwise require repair or replacement based 
upon current guidelines for valvular dysfunction management [62].
For tumors that involve an isolated valve, a standard surgical approach to the 
specific valve is typically employed based on surgeon preference, i.e., trans-right 
atrial for tricuspid pathology and right ventricular masses. For masses such as 
myxomas that involve the intra-atrial septum, a variety of approaches can be used. 
The most common approach is through the right atrium (even if the tumor is on 
the left atrial side of the septum) with excision of the fossa ovalis or the involved 
intra-atrial septum to remove not only the tumor, but the stalk and the potential 
“tumor roots” in the septal tissue (Figure 9). Even with large tumors, primary 
reconstruction of the intra-atrial septum can be often performed as the size (width 
and length) of the associated stalk rarely correlates with the actual extent of septal 
tissue involvement. For large septal defects, reconstruction with bovine pericar-
dium can easily be performed [16]. Depending on surgeon experience, preference, 
and tumor location, a right thoracotomy approach to either the left or right atrium 
can be considered [63]. While a left atrial approach has been described for tumors 
on the left atrial side of the intra-atrial septum, if such an approach is chosen, it is 
critical that the principles of complex tumor excision, including the stalk and septal 
roots (with reconstruction of the intra-atrial septum if necessary), be maintained 
[64]. Merely shaving the tumor off the intra-atrial septum without resecting the 
septal tissue is inappropriate as it might leave residual tumor behind and pre-
dispose to tumor recurrence.
All surgical excisions should be sent for pathology and microbiology. A compre-
hensive pathological evaluation is critical as many tumors have extensive throm-
botic material covering them that might confound a true diagnosis. Occasionally, 
tumors can become infected with presentations similar to endocarditis. When 
encountered, a prolonged course of targeted antibiotic therapy is recommended, 
as with any form of endocarditis. Likewise, microbiologic assessment of the mass 
is necessary to rule out a potentially infectious etiology, especially in the absence 
of a clear preoperative diagnosis. Concomitant infected tumors, while part of any 
differential diagnosis, are rare [65].
Post-operative management should be consistent with that of any other 
post-cardiotomy patient. Anti-coagulation should only be considered if indicated 
for other reasons, such as if recommended by neurologic consultants for the 
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treatment of embolic strokes. For patients whose tumors appear to have a large 
thrombus burden, a hypercoagulable state work-up and appropriate treatment 
should be considered. Guidelines for post-resection imaging surveillance are 
lacking and should be symptom-based unless there is concern for incomplete 
resection or recurrence.
8. Summary
Intra-cardiac masses represent a challenging clinical problem. Patients often pres-
ent with embolic complications or obstructive heart failure symptoms. Alternatively, 
they may be asymptomatic with the mass discovered as an incidental finding in 
work-up of an alternative diagnosis or in preparation for other therapies (i.e., 
coronary artery bypass surgery). As discussed, such tumors are rare and must be 
distinguished from other cardiac masses, specifically endocarditis and intra-cardiac 
thrombus for which the management strategies are well-established. The overriding 
principle of management is prevention of potentially catastrophic embolic complica-
tions, specifically neurologic events. However, the data to support this approach is 
either limited or not based on high-quality randomized or controlled trials [3, 29]. As 
such, when encountered in appropriately risk-stratified patients, surgical removal is 
often curative and should be considered first-line therapy. While STS risk scoring is 
often used to evaluate these patients, a specific risk-model for treatment is not part 
of the STS calculator. However, it most closely matches the risks for patients under-
going valve repair or replacement (http://riskcalc.sts.org/stswebriskcalc/calculate), 
Risk for recurrence is low and post-operative survival is excellent. While medical 
management of these masses is considered in high-risk patients and those who refuse 
surgery, it is important to consider there is little data to support this approach and 
some evidence to suggest an increased stroke risk. Medical management, specifi-
cally anti-thrombotic therapies, have little role and can potentially delay a diagnosis 
until a catastrophic neurologic event occurs. It should only be considered in unusual 
cases. Furthermore, while the mere presence of an intra-cardiac mass is considered 
an indication for surgical resection, if there are concerns about the diagnosis based 
on echocardiographic characteristics or if there is concern for an invasive primary or 
metastatic malignant tumor, CT or MRI imaging can be useful. Given the rarity of 
these tumors, if there are any concerns about the diagnosis or management, referral 
to a tertiary care center should be considered.
Figure 9. 
Surgical specimen of a left atrial myxoma. Approximately 3 cm left atrial cardiac myxoma surgical specimen. 
Note the resected intra-atrial septal tissue.
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9. Conclusions
Intra-cardiac masses are rare, but are occasionally found during work-up for a 
source of embolism or encountered as an incidental finding. Tumor location and 
echocardiographic characteristics often suggest a diagnosis. However, definitive 
surgical resection for both diagnostic and therapeutic reasons should be considered 
first-line therapy. Patients managed non-operatively have increased risk for embolic 
complications. Medical therapies have not been shown to be effective although 
definitive data is lacking and controlled trials may be difficult to perform.
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